Medical device technology firm Stimwave has received a 510(k) clearance from the US Food and Drug Administration (FDA) for its StimQ Peripheral Nerve Stimulator (PNS) System.
StimQ is a small, wireless, micro-technology neuromodulation device developed to offer an alternative to opioids or invasive surgical procedures for patients with chronic pain.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe PNS system is designed to allow ongoing full-body MRI scans under select scanning conditions for the chronic peripheral nerve pain relief.
It can be implanted using a minimally invasive outpatient procedure to treat a variety of pain syndromes such as shoulder pain, upper extremity neuropathy, mid and lower back pain, and lower extremity neuropathy.
Stimwave chairman and CEO Laura Tyler Perryman said: “Thanks to our revolutionary wireless device, we are the only neuromodulation company cleared by the FDA to help patients reduce their chronic neuropathic pain by pinpointing stimulation directly to the affected peripheral nerves with a multi-electrode programmable device, which enables ongoing MRI scans.”
Following the FDA clearance, patients implanted with the device will be eligible to undergo frequent and necessary MRI scans of any body part without the need for removal of the implant.
The StimQ PNS System delivers small pulses of energy in a fully selectable approach to electrodes placed at a peripheral nerve to provide relief by allowing the brain to remap certain pain signals.
Powered by a small, comfortable, flexible wearable external unit, the device is said to be less than 5% of the size of other existing standard implanted options.